|View printer-friendly version|
“A growing dataset continues to highlight the strong performance of the T2MR platform. The diagnostic superiority of the
The T2MR platform is detecting infections missed by blood culture and demonstrates consistently strong performance, as reported by Dr. Clancy in the panel presentation “T2Sepsis Solution: The Impact of Direct from Whole Blood Diagnostics on the Management of Bloodstream Infections.”
T2Candida Panelidentified 37 cases of Candida infections missed by companion blood cultures for patients receiving antifungal therapy in a multi-center DIRECT2 study.
- Findings suggest that T2Candida is more sensitive than blood culture, especially in the presence of antifungal treatment, and a more effective diagnostic tool for patients treated with pre-emptive or empiric antifungal therapy.
- Accumulating data for T2Candida’s performance in clinical practice demonstrate a sensitivity at about 90% and specificity ranging from 98% to 99%.
- HCMC patient analysis suggests the
T2Bacteria Panelwill cover between 85% and 90% of patient cases that come into the hospital through the emergency department.
“I believe the T2Sepsis Solution is the ‘holy grail’ of bloodstream infection diagnostics. No other product can give me virtually hands-free, automated pathogen detection and identification directly from a whole blood sample,” said Dr. Hansen. “With the T2MR platform, I expect my laboratory will get accurate, actionable results to clinicians faster, so patients get on the right treatment earlier when it matters most.”
In addition, the following are highlights from poster presentations at IDWeek 2017:
- New data on the ability of the T2MR platform to detect the superbug Candida auris was presented by
• The T2MR platform successfully identified Candida auris in patient samples at
La Fe Universityand Polytechnic Hospitalin Spain.
• Average time to identification with the T2MR platform was less than 5 hours while time to positive blood culture ranged from 19 to 83 hours prior to subsequent identification.
- The T2MR platform detected infections missed by blood culture and led to the avoidance or de-escalation of unnecessary antifungal therapy at
The T2Candida Paneldemonstrated overall sensitivity of 94.4% and identified 26 proven infections that were not detected by blood culture.
• Negative T2Candida Panel results contributed to the avoidance or de-escalation of antifungal therapy in 64% of these negative patients.
• Negative T2Candida results decreased the average duration of micafungin therapy by 2.1 days.
• The authors concluded that the
T2Candida Paneldemonstrated greater sensitivity for Candida infections and generated results much faster than blood culture.
- The T2MR platform led to reduced use of antifungals and cost savings at
Robert Wood Johnson Hospital.
• Antifungal therapy was avoided or ceased in 67% of patients with a negative T2Candida result and resulted in cost savings due to reduced use of antifungal drugs.
- The T2MR platform identified infections missed by blood culture and reduced the time to initiation of therapy by 1.5 days at the
University of Alabama at BirminghamHospital.
• The authors concluded that the
T2Candida Paneldemonstrated excellent sensitivity (86%) in a real world setting.
• T2Candida identified 23 patients that blood culture missed.
• Rapid T2Candida test results led to accelerating the time to treat patients with the right targeted therapy by 1.5 days.
“Clinical and practical use of the T2MR platform continues to grow, and the impact is being shared by customers who are experiencing the value of the platform’s superior accuracy and time to result when compared to blood culture,” said
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding , product pipeline, anticipated product benefits, goals and strategic priorities, product expansion or opportunities, growth expectations or targets and FDA clearance, as well as statements that include the words “expect,” “intend,” “plan,” “believe,” “project,” “forecast,” “estimate,” “may,” “should,” “anticipate” and similar statements of a future or forward-looking nature. These forward-looking statements are based on management's current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, (i) any inability to (a) realize anticipated benefits from commitments, contracts or products; (b) successfully execute strategic priorities; (c) bring products to market; (d) expand product usage or adoption; (e) obtain customer testimonials; (f) accurately predict growth assumptions; (g) realize anticipated revenues; (h) incur expected levels of operating expenses; or (i) increase the number of high-risk patients at customer facilities; (ii) failure of early data to predict eventual outcomes; (iii) failure to make or obtain anticipated FDA filings or clearances within expected time frames or at all; or (iv) the factors discussed under Item 1A. "Risk Factors" in the company's Annual Report on Form 10-K for the year ended December 31, 2016, filed with the U.S. Securities and Exchange Commission, or SEC, on March 15, 2017, and other filings the company makes with the SEC from time to time. These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While the company may elect to update such forward-looking statements at some point in the future, unless required by law, it disclaims any obligation to do so, even if subsequent events cause its views to change. Thus, one should not assume that the Company’s silence over time means that actual events are bearing out as expressed or implied in such forward-looking statements. These forward-looking statements should not be relied upon as representing the company's views as of any date subsequent to the date of this press release.
Darlene Deptula-Hicks, T2 Biosystems
SVP & Chief Financial Officer
Amy Phillips, Feinstein Kean Healthcare
Chris Brinzey, Westwicke Partners